Q1 Earnings Forecast for IDYA Issued By Leerink Partnrs

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for IDEAYA Biosciences in a report released on Wednesday, February 5th. Leerink Partnrs analyst A. Berens expects that the company will earn ($0.66) per share for the quarter. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($2.45) per share. Leerink Partnrs also issued estimates for IDEAYA Biosciences’ Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.75) EPS, FY2025 earnings at ($2.74) EPS, FY2026 earnings at ($2.81) EPS and FY2027 earnings at ($2.70) EPS.

Several other analysts have also recently commented on the company. Stephens initiated coverage on IDEAYA Biosciences in a report on Monday, November 18th. They issued an “overweight” rating and a $51.00 target price on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Oppenheimer restated an “outperform” rating and issued a $53.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, October 29th. UBS Group started coverage on shares of IDEAYA Biosciences in a research report on Thursday, October 24th. They set a “buy” rating and a $50.00 price target on the stock. Finally, Leerink Partners lowered IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $41.00 to $27.00 in a research report on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $53.67.

IDEAYA Biosciences Trading Down 2.5 %

NASDAQ IDYA opened at $22.42 on Monday. The firm has a market capitalization of $1.94 billion, a PE ratio of -9.62 and a beta of 0.82. The business’s 50-day moving average price is $24.94 and its two-hundred day moving average price is $30.52. IDEAYA Biosciences has a 12 month low of $22.10 and a 12 month high of $47.74.

Institutional Trading of IDEAYA Biosciences

Hedge funds have recently bought and sold shares of the business. State Street Corp lifted its stake in shares of IDEAYA Biosciences by 15.4% in the third quarter. State Street Corp now owns 3,317,936 shares of the company’s stock valued at $105,112,000 after buying an additional 443,640 shares in the last quarter. Barclays PLC boosted its stake in IDEAYA Biosciences by 188.8% during the 3rd quarter. Barclays PLC now owns 181,170 shares of the company’s stock valued at $5,739,000 after purchasing an additional 118,438 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in IDEAYA Biosciences by 12.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 689,073 shares of the company’s stock worth $21,830,000 after purchasing an additional 78,518 shares in the last quarter. Verition Fund Management LLC purchased a new stake in shares of IDEAYA Biosciences in the third quarter worth approximately $246,000. Finally, General American Investors Co. Inc. bought a new position in shares of IDEAYA Biosciences in the third quarter valued at approximately $2,851,000. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.